Balogun Ibrahim O, Roberts Lara N, Patel Raj, Pathansali Rohan, Kalra Lalit, Arya Roopen
King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK; Department of Stroke Medicine, East Kent Hospitals University NHS Foundation Trust, East Kent, UK.
King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Stroke Res Treat. 2016;2016:7940680. doi: 10.1155/2016/7940680. Epub 2016 Dec 25.
. Stroke remains a global leading cause of death and disability. Traditional description of plasma biology in the aftermath of acute ischaemic stroke favours development of hypercoagulability, resulting from complex interplay between plasma and endothelial factors. However, no single assay measures the overall global coagulation process. We postulate that thrombin generation would assist in identifying coagulation abnormalities after acute stroke. . To investigate the coagulation abnormalities after acute ischaemic stroke using thrombin generation. . We evaluated thrombin generation, measured with calibrated automated thrombography in stroke of different aetiological types ( = 170) within 48 hours of symptoms onset (baseline) and in the second week (time 2) and in normal healthy volunteers ( = 71). . Two-point thrombin generation assays showed prolonged lag time and time to peak at baseline (3.3 (2.9, 4.0) versus 3.6 (3.2, 4.7); = 0.005) and (3.3 (2.9, 4.0) versus 3.6 (3.2, 4.7); = 0.002), respectively, and at time 2 (3.5 (2.9, 4.2) versus 4.0 (3.1, 4.9); = 0.004) and (5.9 (5.3, 6.6) versus 6.8 (5.8, 7.7) = 0.05), respectively, in cardioembolic stroke ( = 39), when compared to noncardioembolic stroke ( = 117). The result was reproduced in multiple comparisons between acute ischaemic stroke subgroups and normal healthy volunteers. Endogenous thrombin potential and peak thrombin did not indicate hypercoagulability after acute ischaemic stroke, and thrombolytic therapy did not affect thrombin generation assays. . Our findings suggest that thrombin generation in platelet poor plasma is not useful in defining hypercoagulability in acute ischaemic stroke. This is similar to observed trend in coronary artery disease and contrary to other hypercoagulable states.
中风仍然是全球主要的死亡和残疾原因。传统上对急性缺血性中风后血浆生物学的描述倾向于高凝状态的发展,这是由血浆和内皮因子之间复杂的相互作用导致的。然而,没有单一的检测方法能够测量整个凝血过程。我们推测凝血酶生成有助于识别急性中风后的凝血异常。
为了使用凝血酶生成来研究急性缺血性中风后的凝血异常。
我们在症状发作后48小时内(基线)、第二周(时间2),对不同病因类型的中风患者(n = 170)以及正常健康志愿者(n = 71),采用校准自动血栓形成描记法评估凝血酶生成。
与非心源性栓塞性中风(n = 117)相比,两点凝血酶生成试验显示,在心源性栓塞性中风(n = 39)中,基线时的延迟时间和达到峰值的时间延长(分别为3.3(2.9,4.0)对3.6(3.2,4.7);P = 0.005)和(3.3(2.9,4.0)对3.6(3.2,4.7);P = 0.002),在时间2时分别为(3.5(2.9,4.2)对4.0(3.1,4.9);P = 0.004)和(5.9(5.3,6.6)对6.8(5.8,7.7);P = 0.05)。急性缺血性中风亚组与正常健康志愿者之间的多次比较重现了该结果。内源性凝血酶潜力和凝血酶峰值在急性缺血性中风后并未表明存在高凝状态,溶栓治疗也未影响凝血酶生成试验。
我们的研究结果表明,在血小板缺乏的血浆中凝血酶生成对定义急性缺血性中风中的高凝状态并无用处。这与在冠状动脉疾病中观察到的趋势相似,与其他高凝状态相反。